NM  Vol.2 No.3 , September 2011
A Prospective, Open-Label, 12 Week Trial of S-adenosylmethionine in the Symptomatic Treatment of Alzheimer’s Disease
ABSTRACT
Objective: To determine if treatment with S-adenosylmethionine (SAM-e) might lead to cognitive and behavioral improvement in patients with Alzheimer’s disease (AD). Interventions: We conducted a prospective, open-label study of six subjects who were given oral SAM-e over 12 weeks and measured the effects on cognition and behavior. Outcome measures: Outcome measures of cognition and behavior included the Alzheimer’s Disease Assessment Scale-Cognitive subscale (ADAS-Cog), Mini-Mental State Examination (MMSE), Behave-AD, Clinical Global Impression Scale (CGI), Hamilton Rating Scale for Depression (HAM-D), informant version, Blessed Dementia Scale to assess activities of daily living (ADL), the Physical Self-Maintainance Scale (PSMS), and the Lawton-Brody IADL Scale to measure instrumental activities of daily living. Results: At study completion, two subjects were “moderately improved” and 4 were “minimally improved” on the CGI. Five subjects improved on the ADAS-Cog by an average of 20%. No significant side effects were reported. Conclusions: In this small open label study, SAM-e appeared to have a beneficial effect in patients with AD, but the small subject number didn’t provide enough power to show statistical significance. Controlled trials with adequate statistical power to investigate its utility in AD are warranted.

Cite this paper
nullM. Rudolph, M. Rabinoff and B. Kagan, "A Prospective, Open-Label, 12 Week Trial of S-adenosylmethionine in the Symptomatic Treatment of Alzheimer’s Disease," Neuroscience and Medicine, Vol. 2 No. 3, 2011, pp. 222-225. doi: 10.4236/nm.2011.23030.
References
[1]   T. Bottiglieri, P. Godfrey, T Flynn, et al., “Cerebrospinal Fluid S-adenosylmethionine in Depression and Dementia: Effect of Treatment with Parenteral and Oral S-adenosyl- Methionine,” Journal of Neurology, Neurosurgery and Psychiatry, Vol. 53, 1990, pp. 1096-1098. doi:10.1136/jnnp.53.12.1096

[2]   M Carney, “Serum Folate Values in 423 Psychiatric Patients,” British Medical Journal, Vol. 4, No. 5578, 1967, pp. 512-516. doi:10.1136/bmj.4.5578.512

[3]   E. Reynolds, J. Preece, J. Bailey, et al., “A Folate Deficiency in Depressive Illness,” British Journal of Psychiatry, Vol. 117, No. 538, 1970, pp. 287-292.

[4]   P. S. Godfrey, B. K. Toone, M. W. Carney, et al. “Enhancement of Recovery from Psychiatric Illness by Methylfolate,” Lancet, Vol. 336, No. 8720, 1990, pp. 953- 954.

[5]   T. Bottiglieri, E. Reynolds, B. K. Toone, et al., “CSF S- adenoslymethionine in Neurospcyhatirc Disorders,” Lancet, Vol. 338, No. 8759, 1991, p. 121.

[6]   L. Morrison, D. Smith and S. Kish. “Brain S-adenosylme- thionine Levels Are Severely Decreased in Alzheimer’s Disease,” Journal of Neurochemistry, Vol. 67, No. 3, 1996, pp. 1328-1331. doi:10.1046/j.1471-4159.1996.67031328.x

[7]   T. Bottiglieri, K. Hyland and E. Reynolds. “The Clinical Potential of Ademetionine (S-adenosylmethionine) in Neurological Disorders,” Drugs, Vol. 48, No. 2, 1994, pp. 137-155.

[8]   E. Reynolds, M. Camey, B. Toone, et al., “Transmethylation and Neuropsychiatry,” In: J. M. Mato, Ed., Proceedings of the 1st Conference on Biochemical, Pharmacological and Clinical Aspects of Transmethylation, Jarpyo, Madrid, 1986, pp. 93-102.

[9]   E. Reynolds, P. Godfrey, T. Bottiglieri, et al., “S-adeno- sylmethionine and Alzheimer’s Disease,” Neurology, Vol. 39, Suppl. 1, 1989, p. 397.

[10]   B. Cohen, A. Satlin and G. Zubenko. “S-adenosylmethionine in the Treatment of Alzheimer’s Dementia,” Journal of Clinical Psychopharmacology, Vol. 8, 1988, pp. 43-47.

[11]   M. Cimino, G. Vantini, S. Algeri, et al., “Age-Related Modification of Dopaminergic and Beta-Adrenergic Receptor System: Restoration to Normal Activity by Modifying Membrane Fluidity with S-adenosylmethionine,” Life Sciences, Vol. 34, No. 21, 1984, pp. 2029-2039. doi:10.1016/0024-3205(84)90367-9

[12]   T. Shea and A. Chan, “S-adenosyl Methionine: A Natural Therapeutic Agent Effective against Multiple Hallmarks and Risk Factors Associated with Alzheimer’s Disease,” Journal of Alzheimers Disease, Vol. 13, No. 1, 2008, pp. 67-70.

[13]   B. Kagan, D. Sultzer, N. Rosenlicht and R. Gerner, “Oral S-adenosylmethionine in Depression: A Randomized, Double-Blind, Placebo-Controlled Trial,” American Journal of Psychiatry, Vol. 147, No. 5, 1990; pp. 591- 595.

[14]   “Diagnostic and Statistical Manual of Mental Disorders,” 4th Edition, American Psychiatric Association Press, Washington D.C., 1994.

[15]   W. Rosen, R. Mohs and K. Davis. “A New Rating Scale for Alzheimer’s Disease,” American Journal of Psychiatry, Vol. 141, No. 11, 1984, pp. 1356-1364.

[16]   M. Folstein, S. Folstein and P. McHugh, “Mini-Mental State: A Practical Method for Grading the Cognitive State of Patients for the Clinician,” Journal of Psychiatric Research, Vol. 12, No. 3, 1975, pp. 189-198. doi:10.1016/0022-3956(75)90026-6

[17]   B. Reisberg, “Alzheimer’s Disease,” In: E. Sadavoy, L. Lazarus, L. Jarvik, and G. Grossberg , Eds., Comprehensive Review of Geriatric Psychiatry II, American Psychiatric Press, Inc., Washington D.C., 1996, p. 430.

[18]   B. Reisberg, J. Borenstein, S. Salob, et al., “Behavioral Symptoms in Alzheimer’S Disease: Phenomenology and Treatment,” Journal of Clinical Psychiatry, Vol. 48, Suppl. 5, 1987, pp. 9-15.

[19]   M. Hamilton, “A Rating Scale for Depression,” Journal of Neurology, Neurosurgery and Psychiatry, Vol. 23, No. 1, pp. 56-62. doi:10.1136/jnnp.23.1.56

[20]   G. Blessed, B. E. Tomlinson and M. Roth, “The Association between Quantitative Measures of Dementia and of Senile Change in the Cerebral Grey Matter of Elderly Subjects,” British Journal of Psychiatry, Vol. 114, No. 512, 1968, pp. 797-811. doi:10.1192/bjp.114.512.797

[21]   M. P. Lawton and E. M. Brody, “Assessment of Older People: Self-maintaining and Instrumental Activities of Daily Living,” Gerontologist, Vol. 9, No. 3, 1969, pp. 179-186.

[22]   E. Peskind, “Pharmacologic Approaches to Cognitive Deficits in Alzheimer’s Disease,” Journal of Clinical Psychiatry, Vol. 59, Suppl. 9, 1998, pp. 22-27.

[23]   G. Small, P. Rabins, P. Barry, et al., “Diagnosis and Treatment of Alzheimer Disease and Related Disorders,” Journal of the American Medical Association, Vol. 278, No. 16, 1997, pp. 1363-1371. doi:10.1001/jama.278.16.1363

[24]   S. Scarpa, A. Fuso, et al., “Presenilin 1 Gene Silencing by S-adenosylmethionine: A Treatment For Alzheimer’s Disease?” FEBS Letters, Vol. 541, 2003, pp. 145-148. doi:10.1016/S0014-5793(03)00277-1

 
 
Top